Dingwei Ye

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 20

Top Topics

Radical Prostatectomy

Dna Damage Response

Top Venues

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Guowen Lin, Feng Zhang, Xiaoling Weng, Zhe Hong, Dingwei Ye, Gangmin Wang
Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer: a comprehensive study using sequencing and animal models. Oncogene 43 (31) (2024)
Wen-Hao Xu, Jiahe Lu, Xi Tian, Shiqi Ye, Shiyin Wei, Jun Wang, Aihetaimujiang Anwaier, Yuanyuan Qu, Wang-Rui Liu, Kun Chang, Hai-Liang Zhang, Dingwei Ye
Unveiling the impact of tertiary lymphoid structures on immunotherapeutic responses of clear cell renal cell carcinoma. MedComm 5 (1) (2024)
Guowen Lin, Feng Zhang, Xiaoling Weng, Zhe Hong, Dingwei Ye, Gangmin Wang
Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer: a comprehensive study using sequencing and animal models. Oncogene (2024)
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, Andre P Fay, Ugo De Giorgi, Jae Young Joung, Peter C C Fong, Eric Voog, Robert J Jones, Neal D Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G Healy, Nicola Di Santo, A Douglas Laird, Fabian Zohren, Archana M Agarwal
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature medicine (2024)
Guowen Lin, Feng Zhang, Xiaoling Weng, Zhe Hong, Dingwei Ye, Gangmin Wang
Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer: a comprehensive study using sequencing and animal models. Oncogene 43 (31) (2024)
Guowen Lin, Feng Zhang, Xiaoling Weng, Zhe Hong, Dingwei Ye, Gangmin Wang
Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer: a comprehensive study using sequencing and animal models. Oncogene 43 (31) (2024)
Wen-Hao Xu, Jiahe Lu, Xi Tian, Shiqi Ye, Shiyin Wei, Jun Wang, Aihetaimujiang Anwaier, Yuanyuan Qu, Wang-Rui Liu, Kun Chang, Hai-Liang Zhang, Dingwei Ye
Unveiling the impact of tertiary lymphoid structures on immunotherapeutic responses of clear cell renal cell carcinoma. MedComm 5 (1) (2024)
Wen-Hao Xu, Jianfeng Yang, Shiqi Ye, Wangrui Liu, Jiahe Lu, Aihetaimujiang Anwaier, Hai-Liang Zhang, Dingwei Ye
Insights into the maturation heterogeneity of tumor-associated tertiary lymphoid structures in cancer immunotherapy. Immunotherapy 16 (3) (2023)
Maha H A Hussain, Bertrand Tombal, Fred Saad, Karim Fizazi, Cora N Sternberg, E David Crawford, Neal D Shore, Evgeny Kopyltsov, Arash Rezazadeh Kalebasty, Martin Boegemann, Dingwei Ye, Felipe José Silva Melo Cruz, Hiroyoshi Suzuki, Shivani Kapur, Shankar Srinivasan, Frank Verholen, Iris Kuss, Heikki Joensuu, Matthew R Smith
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Hai-Liang Zhang, Lin Bai, Xin-Qiang Wu, Xi Tian, Jinwen Feng, Xiaohui Wu, Guo-Hai Shi, Xiaoru Pei, Jiacheng Lyu, Guojian Yang, Yang Liu, Wenhao Xu, Aihetaimujiang Anwaier, Yu Zhu, Da-Long Cao, Fu-Jiang Xu, Yue Wang, Hua-Lei Gan, Meng-Hong Sun, Jian-Yuan Zhao, Yuanyuan Qu, Dingwei Ye, Chen Ding
Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor. Nature communications 14 (1) (2023)
Yu Wei, Tingwei Zhang, Beihe Wang, Jian Pan, Shengming Jin, Bangwei Fang, Weijie Gu, Xiaojian Qin, Bo Dai, Guowen Lin, Hualei Gan, Junlong Wu, Dingwei Ye, Yao Zhu
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity. Molecular oncology (2023)
Kun Chang, Yingji Chen, Xuanzhi Zhang, Wei Zhang, Ning Xu, Bohan Zeng, Yue Wang, Tao Feng, Bo Dai, Fu-Jiang Xu, Dingwei Ye, Chenji Wang
DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma. Cancer research (2023)
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, Andre P Fay, Ugo De Giorgi, Jae Young Joung, Peter C C Fong, Eric Voog, Robert J Jones, Neal D Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G Healy, Nicola Di Santo, A Douglas Laird, Fabian Zohren, Archana M Agarwal
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature medicine (2023)
Wen-Hao Xu, Jianfeng Yang, Shiqi Ye, Wangrui Liu, Jiahe Lu, Aihetaimujiang Anwaier, Hai-Liang Zhang, Dingwei Ye
Insights into the maturation heterogeneity of tumor-associated tertiary lymphoid structures in cancer immunotherapy. Immunotherapy 16 (3) (2023)
Rui Sun, Binyuan Yan, Hao Li, Dongling Ding, Liguo Wang, Pang Jun, Dingwei Ye, Zhenlin Huang
Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis. Cancer research (2023)
Wen-Hao Xu, Jianfeng Yang, Shiqi Ye, Wangrui Liu, Jiahe Lu, Aihetaimujiang Anwaier, Hai-Liang Zhang, Dingwei Ye
Insights into the maturation heterogeneity of tumor-associated tertiary lymphoid structures in cancer immunotherapy. Immunotherapy (2023)
Xiaojian Qin, Dongmei Ji, Weijie Gu, Weiqing Han, Hong Luo, Chuanjun Du, Qing Zou, Zhongquan Sun, Chaohong He, Shaoxing Zhu, Tie Chong, Xin Yao, Ben Wan, Xinfeng Yang, Aobing Bai, Chunlei Jin, Jianjun Zou, Dingwei Ye
Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial. BMC medicine 20 (1) (2022)
Yuanyuan Qu, Xiaohui Wu, Aihetaimujiang Anwaier, Jinwen Feng, Wenhao Xu, Xiaoru Pei, Yu Zhu, Yang Liu, Lin Bai, Guojian Yang, Xi Tian, Jiaqi Su, Guo-Hai Shi, Da-Long Cao, Fu-Jiang Xu, Yue Wang, Hua-Lei Gan, Shujuan Ni, Meng-Hong Sun, Jian-Yuan Zhao, Hai-Liang Zhang, Dingwei Ye, Chen Ding
Proteogenomic characterization of MiT family translocation renal cell carcinoma. Nature communications 13 (1) (2022)
Kim N Chi, Simon Chowdhury, Anders Bjartell, Byung Ha Chung, Andrea Juliana Pereira de Santana Gomes, Robert Given, Alvaro Juárez, Axel S Merseburger, Mustafa Özgüroğlu, Hirotsugu Uemura, Dingwei Ye, Sabine Brookman-May, Suneel D Mundle, Sharon A McCarthy, Julie S Larsen, Weili Sun, Katherine B Bevans, Ke Zhang, Nibedita Bandyopadhyay, Archana M Agarwal
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (20) (2021)
Dalin He, Zhongquan Sun, Jianming Guo, Zhigen Zhang, Yuxi Shan, Lulin Ma, Hanzhong Li, Jie Jin, Yiran Huang, Jiaquan Xiao, Qiang Wei, Dingwei Ye
A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China. Asia-Pacific journal of clinical oncology 15 (3) (2019)